Zacks Investment Research reported on Stemline Therapeutics Inc (NASDAQ:STML), stepping up its target to $12.00 earlier today
- Updated: October 9, 2016
Boasting a price of $11.05, Stemline Therapeutics Inc (NASDAQ:STML) traded 12.63% higher on the day. With the last stock price close up 70.36% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Stemline Therapeutics Inc has recorded a 50-day average of $9.42 and a two hundred day average of $7.23. Volume of trade was up over the average, with 527,593 shares of STML changing hands over the typical 153,005
Zacks Investment Research upped the price target of Stemline Therapeutics Inc (NASDAQ:STML) to $12.00 indicating a possible upside of 0.09%.
On 11/10/2015, Roth Capital released a statement for Stemline Therapeutics Inc (NASDAQ:STML) bumped down the target price from $50.00 to $32.00 that suggested an upside of 2.56%.
With a total market value of $0, Stemline Therapeutics Inc has with a one year low of $3.88 and a one year high of $12.61 .
A total of 5 equity analysts have released a ratings update on STML. Three equity analysts rating the company a strong buy, three equity analysts rating the company a buy, zero equity analysts rating the company a hold, zero equity analysts rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $31.20.
Brief Synopsis About Stemline Therapeutics Inc (NASDAQ:STML)
Stemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers. SL-401 consists of IL-3 recombinantly fused to a truncated diphtheria toxin payload. SL-701 is an immunotherapy designed to activate the immune system to attack tumors. SL-701 comprises various short synthetic peptides that correspond to epitopes of targets, including IL-13 receptor subunit alpha-2 (IL-13Ra2), ephrin type-A receptor 2 (EphA2) and survivin, present on brain cancer. SL-801 is an oral, small molecule that reversibly inhibits Exportin-1 (XPO1), also known as Chromosome Region Maintenance-1 (CRM-1), a nuclear transport protein.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.